Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

CORRECTION - Veloxis Pharmaceuticals A/S Raises FY 2013 Earnings Guidance


Wednesday, 13 Nov 2013 02:00pm EST 

HEADLINE CORRECTED TO READ...Raises FY 2013 Earnings Guidance...INSTEAD OF...Lowers FY 2013 Earnings Guidance Veloxis Pharmaceuticals A/S announced that for fiscal 2013, the Company has improved their earnings guidance and now expects an operating and net loss in the range of DKK 160 million - DKK 190 million. According to I/B/E/S estimates, analysts on average are expecting the Company to report operating profit (EBIT) of negative DKK 188.50 million and net income of negative DKK 183.50 million for fiscal 2013. 

Company Quote

0.88
-0.01 -1.12%
5 Mar 2012